Perspective Therapeutics (CATX) Net Margin Growth (1y) (2011 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) Net Margin Growth (1y) (2011 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,043.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -753,036.00 |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -40,478.00 |
| Jun 30, 2023 | -57,111.00 |
| Mar 31, 2023 | -4,276.00 |
| Sep 30, 2022 | -1,758.00 |
| Jun 30, 2022 | 78.00 |
| Mar 31, 2022 | -1,763.00 |
| Dec 31, 2021 | -2,016.00 |
| Sep 30, 2021 | -5,745.00 |
| Jun 30, 2021 | 1,311.00 |
| Mar 31, 2021 | -963.00 |
| Dec 31, 2020 | 396.00 |
| Sep 30, 2020 | 534.00 |
| Jun 30, 2020 | 481.00 |
| Mar 31, 2020 | 3,970.00 |
| Dec 31, 2019 | 3,362.00 |
| Sep 30, 2019 | 6,136.00 |
| Jun 30, 2019 | 9,022.00 |
| Mar 31, 2019 | 2,614.00 |
| Dec 31, 2018 | 2,107.00 |
| Sep 30, 2018 | 3,118.00 |